Chiesi Mexico’s Marco Ruggiero discusses his initial impressions of the Mexican pharma market, his strategic priorities for the affiliate, and the increasing importance of the company’s respiratory portfolio in Mexico.
With respiratory diseases, there is sometimes the erroneous perception that they are not as severe or urgent as other conditions. Nevertheless, COPD is already one of the leading causes of death globally and many countries are increasing their investment in this disease area
Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and the impact of the country’s ongoing health reforms. In my experience,…
Recently appointed CEO and president for Pfizer Mexico, Constanza Losada, outlines the exciting challenge of taking on leadership for such an important affiliate during the COVID-19 pandemic and how Pfizer…
UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region…
The latest from Mexican pharma, including government talks with Indian authorities to provide low-cost medicines, a new distribution pilot program led by the military, the authorization of two Lilly monoclonal…
Writing in the November issue of DIA Global Forum, Lawrence Liberti, Mario Alanis, Pravin Chopra, and Silvia Bendiner examine how the COVID-19 pandemic facilitated greater inter-stakeholder collaboration across the healthcare…
The latest from the healthcare industry in Latin America, including an alarming OECD report about the decline of well-being in the region due to Covid-19, Bayer’s USD 350 million investment…
See our Cookie Privacy Policy Here